{
    "clinical_study": {
        "@rank": "112716", 
        "arm_group": [
            {
                "arm_group_label": "MK-0893 40 mg\u2192MK-0893 200 mg\u2192placebo", 
                "arm_group_type": "Experimental", 
                "description": "In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine\u00ae (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine\u00ae, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs."
            }, 
            {
                "arm_group_label": "MK-0893 200 mg\u2192placebo\u2192MK-0893 10 mg", 
                "arm_group_type": "Experimental", 
                "description": "In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine\u00ae (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine\u00ae, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs."
            }, 
            {
                "arm_group_label": "Placebo\u2192MK-0893 10 mg\u2192MK-0893 40 mg", 
                "arm_group_type": "Experimental", 
                "description": "In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine\u00ae (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine\u00ae, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs."
            }, 
            {
                "arm_group_label": "MK-0893 10 mg\u2192MK-0893 40 mg\u2192MK-0893 200 mg", 
                "arm_group_type": "Experimental", 
                "description": "In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine\u00ae (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine\u00ae, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs."
            }, 
            {
                "arm_group_label": "Placebo\u2192MK-0893 1000 mg\u2192MK-0893 200 mg", 
                "arm_group_type": "Experimental", 
                "description": "In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine\u00ae (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine\u00ae, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs."
            }, 
            {
                "arm_group_label": "MK-0893 200 mg\u2192placebo\u2192MK-0893 1000 mg", 
                "arm_group_type": "Experimental", 
                "description": "In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine\u00ae (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine\u00ae, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs."
            }, 
            {
                "arm_group_label": "MK-0893 1000 mg\u2192MK-0893 200 mg\u2192placebo", 
                "arm_group_type": "Experimental", 
                "description": "In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine\u00ae (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine\u00ae, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study to assess the pharmacokinetics, safety, and tolerability of sequential\n      single oral doses of MK-8093 10 mg, 40 mg, 200 mg, or placebo to MK-8093 (Part 1) depending\n      on treatment assignment in young healthy male participants.  In Part 2 of this study,\n      sequential single oral doses of MK-8093 200 mg, 1000 mg or placebo to MK-8093 depending on\n      treatment assignment will be evaluated. The primary hypothesis of the study is that at least\n      one dose of MK-0893 will produce greater reduction of glucagon-induced glycemia as compared\n      to placebo following the infusion of glucagon, Sandostatine\u00ae, and basal insulin."
        }, 
        "brief_title": "A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine\u00ae and Insulin (MK-0893-002)", 
        "completion_date": {
            "#text": "December 2005", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Good health\n\n          -  Body Mass Index of between 18 and 28 kg/m^2, or up to 30 kg/m^2 with approval of\n             sponsor\n\n          -  Non-smoker for at least 6 months\n\n          -  Willing to avoid strenuous physical activity\n\n          -  Willing to avoid alcohol, caffeine, and grapefruit juice consumption\n\n        Exclusion Criteria:\n\n          -  History of renal, neurologic, gastrointestinal or respiratory disease or any\n             gastrointestinal surgery\n\n          -  History of multiple and/or severe allergies to a prescription, nonprescription or\n             investigational drug or food\n\n          -  History of any cardiovascular/cardiac disease\n\n          -  History of any hepatic disease and primary biliary cirrhosis\n\n          -  History of hypoglycemia or glucose intolerance, type 1 diabetes, or type 2 diabetes\n\n          -  Requires or anticipates use of prescription or nonprescription medications, including\n             herbal remedies\n\n          -  A user of any illicit drugs or a history of drug or alcohol abuse\n\n          -  Surgery, donated a unit of blood, or participated in another clinical study within 4\n             weeks prior to study participation\n\n          -  History of hypersensitivity to insulin, glucagon, or Sandostatine\u00ae."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02012166", 
            "org_study_id": "0893-002", 
            "secondary_id": "2005-002198-57"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "MK-0893 200 mg\u2192placebo\u2192MK-0893 10 mg", 
                    "Placebo\u2192MK-0893 10 mg\u2192MK-0893 40 mg", 
                    "MK-0893 10 mg\u2192MK-0893 40 mg\u2192MK-0893 200 mg"
                ], 
                "description": "MK-0893 10 mg administered orally in 240 mL of water", 
                "intervention_name": "MK-0893 10 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MK-0893 40 mg\u2192MK-0893 200 mg\u2192placebo", 
                    "Placebo\u2192MK-0893 10 mg\u2192MK-0893 40 mg", 
                    "MK-0893 10 mg\u2192MK-0893 40 mg\u2192MK-0893 200 mg"
                ], 
                "description": "MK-0893 40 mg administered orally in 240 mL of water", 
                "intervention_name": "MK-0893 40 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MK-0893 40 mg\u2192MK-0893 200 mg\u2192placebo", 
                    "MK-0893 200 mg\u2192placebo\u2192MK-0893 10 mg", 
                    "MK-0893 10 mg\u2192MK-0893 40 mg\u2192MK-0893 200 mg", 
                    "Placebo\u2192MK-0893 1000 mg\u2192MK-0893 200 mg", 
                    "MK-0893 200 mg\u2192placebo\u2192MK-0893 1000 mg", 
                    "MK-0893 1000 mg\u2192MK-0893 200 mg\u2192placebo"
                ], 
                "description": "MK-0893 200 mg administered orally in 240 mL of water", 
                "intervention_name": "MK-0893 200 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Placebo\u2192MK-0893 1000 mg\u2192MK-0893 200 mg", 
                    "MK-0893 200 mg\u2192placebo\u2192MK-0893 1000 mg", 
                    "MK-0893 1000 mg\u2192MK-0893 200 mg\u2192placebo"
                ], 
                "description": "MK-0893 1000 mg administered orally in 240 mL of water", 
                "intervention_name": "MK-0893 1000 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MK-0893 40 mg\u2192MK-0893 200 mg\u2192placebo", 
                    "MK-0893 200 mg\u2192placebo\u2192MK-0893 10 mg", 
                    "Placebo\u2192MK-0893 10 mg\u2192MK-0893 40 mg", 
                    "Placebo\u2192MK-0893 1000 mg\u2192MK-0893 200 mg", 
                    "MK-0893 200 mg\u2192placebo\u2192MK-0893 1000 mg", 
                    "MK-0893 1000 mg\u2192MK-0893 200 mg\u2192placebo"
                ], 
                "description": "Placebo administered orally in 240 mL of water", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MK-0893 40 mg\u2192MK-0893 200 mg\u2192placebo", 
                    "MK-0893 200 mg\u2192placebo\u2192MK-0893 10 mg", 
                    "Placebo\u2192MK-0893 10 mg\u2192MK-0893 40 mg", 
                    "MK-0893 10 mg\u2192MK-0893 40 mg\u2192MK-0893 200 mg", 
                    "Placebo\u2192MK-0893 1000 mg\u2192MK-0893 200 mg", 
                    "MK-0893 200 mg\u2192placebo\u2192MK-0893 1000 mg", 
                    "MK-0893 1000 mg\u2192MK-0893 200 mg\u2192placebo"
                ], 
                "description": "Sandostatine\u00ae is a somatostatin analogue. At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine\u00ae, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous Sandostatine\u00ae will be administered at 30 ng/kg/min.", 
                "intervention_name": "Sandostatine\u00ae", 
                "intervention_type": "Biological", 
                "other_name": "Octreotide acetate"
            }, 
            {
                "arm_group_label": [
                    "MK-0893 40 mg\u2192MK-0893 200 mg\u2192placebo", 
                    "MK-0893 200 mg\u2192placebo\u2192MK-0893 10 mg", 
                    "Placebo\u2192MK-0893 10 mg\u2192MK-0893 40 mg", 
                    "MK-0893 10 mg\u2192MK-0893 40 mg\u2192MK-0893 200 mg", 
                    "Placebo\u2192MK-0893 1000 mg\u2192MK-0893 200 mg", 
                    "MK-0893 200 mg\u2192placebo\u2192MK-0893 1000 mg", 
                    "MK-0893 1000 mg\u2192MK-0893 200 mg\u2192placebo"
                ], 
                "description": "At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine\u00ae, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous insulin will be administered at 0.10 milli-international unit (mIU)/kg/min.", 
                "intervention_name": "Insulin", 
                "intervention_type": "Biological", 
                "other_name": "Humuline Regular, Insulin for human injection"
            }, 
            {
                "arm_group_label": [
                    "MK-0893 40 mg\u2192MK-0893 200 mg\u2192placebo", 
                    "MK-0893 200 mg\u2192placebo\u2192MK-0893 10 mg", 
                    "Placebo\u2192MK-0893 10 mg\u2192MK-0893 40 mg", 
                    "MK-0893 10 mg\u2192MK-0893 40 mg\u2192MK-0893 200 mg", 
                    "Placebo\u2192MK-0893 1000 mg\u2192MK-0893 200 mg", 
                    "MK-0893 200 mg\u2192placebo\u2192MK-0893 1000 mg", 
                    "MK-0893 1000 mg\u2192MK-0893 200 mg\u2192placebo"
                ], 
                "description": "At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine\u00ae, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous glucagon will be administered at 3 ng/kg/min.", 
                "intervention_name": "Glucagon", 
                "intervention_type": "Biological", 
                "other_name": "Glucagen"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glucagon", 
                "Glucagon-Like Peptide 1", 
                "Octreotide", 
                "Insulin", 
                "Molecular Mechanisms of Pharmacological Action", 
                "Physiological Effects of Drugs"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Diabetes Mellitus", 
            "Diabetes Mellitus, Type 2", 
            "Glucose Metabolism Disorders", 
            "Metabolic Diseases", 
            "Endocrine System Diseases", 
            "Therapeutic Uses", 
            "Pharmacologic Actions", 
            "Molecular Mechanisms of Pharmacological Action", 
            "Physiological Effects of Drugs"
        ], 
        "lastchanged_date": "February 5, 2014", 
        "number_of_arms": "7", 
        "official_title": "A Double-Blind, Randomized, Placebo-Controlled, Single-Dose, 3-Period, 4 Treatment Incomplete Crossover Study to Assess the Effects of Single Oral Doses of L-001241689 on Glucagon-Induced Glycemic Excursion in Healthy Male Subjects Following Intravenous Administration of Glucagon, Sandostatine\u00ae and Insulin", 
        "overall_official": {
            "affiliation": "Merck Sharp & Dohme Corp.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2005", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Post-infusion Incremental Glucose Area Under the Plasma Concentration Versus Time Curve [AUC0-240 min] Study Part 1", 
                "safety_issue": "No", 
                "time_frame": "Up to 76 hours postdose"
            }, 
            {
                "measure": "Post-infusion Incremental Glucose Area Under the Plasma Concentration Versus Time Curve [AUC0-240 min] Study Part 2", 
                "safety_issue": "No", 
                "time_frame": "Up to 124 hours postdose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02012166"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of Participants With An Adverse Event (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 12 weeks"
            }, 
            {
                "measure": "Number of Participants Who Discontinued Study Treatment Due To AEs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 21 days of each treatment period"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2005", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}